Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

NCT01500083 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Indolent Non-Hodgkin's Lymphoma
Chronic Lymphocytic Leukemia

Interventions

DRUG: Bendamustine at a dose of 100 mg/m2
DRUG: Bendamustine at a dose of 120 mg/m2

Sponsor

Lundbeck Canada Inc.